Evidence map›Paper›PMID 38845003›Full record

ArticleJournal of translational medicine2024

Factor of time in dendritic cell (DC) maturation: short-term activation of DCs significantly improves type 1 cytokine production and T cell responses.

Primož Poženel, Kaja Zajc, Urban Švajger

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Primož PoženelSlovenian Institute for Transfusion Medicine, Šlajmerjeva 6, Ljubljana, 1000, Slovenia.
Kaja ZajcSlovenian Institute for Transfusion Medicine, Šlajmerjeva 6, Ljubljana, 1000, Slovenia.
Urban ŠvajgerSlovenian Institute for Transfusion Medicine, Šlajmerjeva 6, Ljubljana, 1000, Slovenia. urban.svajger@ztm.si.ORCID 0000-0002-1908-4254

Funding

Javna Agencija za Raziskovalno Dejavnost RS J1-4417Javna Agencija za Raziskovalno Dejavnost RS P3-0371
6 · The paper itself

Abstract

Dendritic cells (DCs) have been intensively studied in correlation to tumor immunology and for the development DC-based cancer vaccines. Here, we present the significance of the temporal aspect of DC maturation for the most essential subsequent timepoint, namely at interaction with responding T cells or after CD40-Ligand restimulation. Mostly, DC maturation is still being achieved by activation processes which lasts 24 h to 48 h. We hypothesized this amount of time is excessive from a biological standpoint and could be the underlying cause for functional exhaustion. Indeed, shorter maturation periods resulted in extensive capacity of monocyte-derived DCs to produce inflammatory cytokines after re-stimulation with CD40-Ligand. This effect was most evident for the primary type 1 polarizing cytokine, IL-12p70. This capacity reached peak at 6 h and dropped sharply with longer exposure to initial maturation stimuli (up to 48 h). The 6 h maturation protocol reflected superiority in subsequent functionality tests. Namely, DCs displayed twice the allostimulatory capacity of 24 h- and 48 h-matured DCs. Similarly, type 1 T cell response measured by IFN-γ production was 3-fold higher when CD4

Indexed as

Cell DifferentiationCytokinesDendritic CellsCD40 LigandCD8-Positive T-LymphocytesHumansLymphocyte ActivationTime FactorsT-LymphocytesCD40 LigandCytokinesAnti-tumor responsesCancerCytotoxic T cellsDendritic cellsMaturationVaccines

Identifiers

PMID38845003
PMCPMC11155046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.